Cyfuse Biomedical K.K Management
Management criteria checks 2/4
Cyfuse Biomedical K.K's CEO is Shizuka Akieda, appointed in Mar 2018, has a tenure of 6.83 years. directly owns 4.26% of the company’s shares, worth ¥151.96M. The average tenure of the management team and the board of directors is 6.8 years and 4.8 years respectively.
Key information
Shizuka Akieda
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 6.8yrs |
| CEO ownership | 4.3% |
| Management average tenure | 6.8yrs |
| Board average tenure | 4.8yrs |
CEO
Shizuka Akieda (48 yo)
6.8yrs
Tenure
Ms. Shizuka Akieda serves as Chief Executive Officer since March 2018 & Director since September 2016 at Cyfuse Biomedical K.K. respectively. She served as researcher in genomics and regenerative medicine...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.8yrs | no data | 4.26% ¥ 152.0m | |
| Co-Founder | no data | no data | no data | |
| CFO, Head of Corporate Planning & Business Administration and Director | 6.8yrs | no data | 2.94% ¥ 104.8m | |
| GM of System Development Department & Director | 3.8yrs | no data | 0.19% ¥ 6.8m |
6.8yrs
Average Tenure
48yo
Average Age
Experienced Management: 4892's management team is seasoned and experienced (6.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 8.3yrs | no data | 4.26% ¥ 152.0m | |
| CFO, Head of Corporate Planning & Business Administration and Director | 6.8yrs | no data | 2.94% ¥ 104.8m | |
| GM of System Development Department & Director | 3.8yrs | no data | 0.19% ¥ 6.8m | |
| Independent Outside Director | 5.8yrs | no data | no data | |
| Audit & Supervisory Board Member | 6.6yrs | no data | no data | |
| Audit & Supervisory Board Member | 3.8yrs | no data | no data | |
| Audit & Supervisory Board Member | 3.8yrs | no data | no data | |
| Independent Outside Director | 3.8yrs | no data | no data |
4.8yrs
Average Tenure
50.5yo
Average Age
Experienced Board: 4892's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 04:46 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cyfuse Biomedical K.K. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|